Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Vanderbilt University Medical Center

Sites in Nashville, TN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1269
Shown on this page
12
Current sort
Recently updated
Campus scope
Vanderbilt University Medical Center, Nashville, TN
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Vanderbilt University Medical Center, Nashville, TN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 997–1008 of 1,269 matching trials with a site at Vanderbilt University Medical Center, Nashville, TN.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Not applicable Interventional

PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

NCT05313165
Status at this site: Recruiting
View directory record Official record
Conditions
Critical Limb Ischemia, Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease
Interventions
LimFlow Stent Graft System
Device
Lead sponsor
LimFlow, Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
30
States / cities
La Jolla, California • Palo Alto, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Nov 9, 2026, 1:46 PM EST
Recruiting Phase 3 Interventional

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

NCT05659381
Status at this site: Recruiting
View directory record Official record
Conditions
Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
Interventions
Cisplatin, No treatment
Drug · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
59
States / cities
Duarte, California • La Jolla, California • Newport Beach, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Nov 9, 2026, 1:46 PM EST
Recruiting No phase listed Observational

Lupus Landmark Study: A Prospective Registry and Biorepository

NCT05934149
Status at this site: Recruiting
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Lupus Research Alliance
Other
Eligibility
18 Years to 110 Years
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Nov 9, 2026, 1:46 PM EST
Active, not recruiting Early Phase 1 Interventional

The Gut, Liver And Metabolome in Human Immunodeficiency Virus and Non Alcoholic Fatty Liver Disease

NCT06113003
Site status not listed — check the official record
View directory record Official record
Conditions
HIV, Non-Alcoholic Fatty Liver Disease, Metabolic-Associated Steatotic Liver Disease
Interventions
Prebiotic, Probiotic
Dietary Supplement
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Nov 9, 2026, 1:46 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Exercise Testing After Preeclampsia

NCT06741436
Status at this site: Recruiting
View directory record Official record
Conditions
Preeclampsia, Heart Failure Preserved Ejection Fraction, Hypertension
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Nov 9, 2026, 1:46 PM EST
Active, not recruiting Not applicable Interventional

Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea (DREAM)

NCT03868618
Site status not listed — check the official record
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Genio™ system
Device
Lead sponsor
Nyxoah S.A.
Industry
Eligibility
22 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
16
States / cities
Birmingham, Alabama • Boca Raton, Florida • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Nov 9, 2026, 1:46 PM EST
Recruiting No phase listed Observational

Registry for Stage 2 Type 1 Diabetes

NCT06481904
Status at this site: Recruiting
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
TZIELD (teplizumab-mzwv)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
37
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 9, 2026, 1:46 PM EST
Active, not recruiting Phase 3 Interventional

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT04524611
Site status not listed — check the official record
View directory record Official record
Conditions
Crohn's Disease (CD)
Interventions
Risankizumab, Ustekinumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
72
States / cities
Chandler, Arizona • Coronado, California • Irvine, California + 62 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 9, 2026, 1:46 PM EST
Recruiting Phase 4 Interventional

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

NCT05390892
Status at this site: Recruiting
View directory record Official record
Conditions
Type2Diabetes, ASCVD
Interventions
SGLT2 inhibitor, GLP-1 receptor agonist
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
36
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 9, 2026, 1:46 PM EST
Active, not recruiting Phase 2 Interventional

A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

NCT03401788
Site status not listed — check the official record
View directory record Official record
Conditions
VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation, VHL Syndrome, VHL Gene Inactivation, VHL-Associated Renal Cell Carcinoma, VHL-Associated Clear Cell Renal Cell Carcinoma
Interventions
Belzutifan
Drug
Lead sponsor
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
8
States / cities
Bethesda, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 9, 2026, 1:46 PM EST
Active, not recruiting Phase 2 Interventional

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06290934
Site status not listed — check the official record
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
emvistegrast, Placebo-to-match emvistegrast
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
57
States / cities
Peoria, Arizona • Camarillo, California • Garden Grove, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 9, 2026, 1:46 PM EST
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Quantitative Imaging of Brain Glymphatic Function in Humans

NCT04768101
Site status not listed — check the official record
View directory record Official record
Conditions
Parkinson Disease
Interventions
[11C]-PIB
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
55 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 9, 2026, 1:46 PM EST

About this Vanderbilt University Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Vanderbilt University Medical Center in Nashville, TN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.